Onconetix (NASDAQ:ONCO) Posts Quarterly Earnings Results, Beats Estimates By $44,973.99 EPS

Onconetix (NASDAQ:ONCO – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($76.01) earnings per share for the quarter, topping the consensus estimate of ($45,050.00) by $44,973.99, FiscalAI reports. Onconetix had a negative return on equity of 91.95% and a negative net margin of 1,575.89%. The company had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.02 million.

Onconetix Stock Down 9.3%

Shares of NASDAQ:ONCO traded down $0.30 during midday trading on Monday, reaching $2.91. 62,174 shares of the company traded hands, compared to its average volume of 167,959. The firm’s fifty day moving average price is $6.09 and its two-hundred day moving average price is $106.54. The firm has a market capitalization of $1.72 million, a price-to-earnings ratio of 0.00 and a beta of 2.62. Onconetix has a 12 month low of $2.76 and a 12 month high of $1,610.00.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ONCO. Wall Street Zen upgraded Onconetix from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings upgraded shares of Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on ONCO

Onconetix Company Profile

(Get Free Report)

Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.

Read More

Earnings History for Onconetix (NASDAQ:ONCO)

Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.